Moneycontrol
HomeNewsBusinessMarketsSyngene eyes recovery in H2FY25, plans to triple bio-manufacturing capacity by FY26
Trending Topics

Syngene eyes recovery in H2FY25, plans to triple bio-manufacturing capacity by FY26

Syngeme has major infrastructure projects slated for completion by FY26. The company aims to triple its bio-manufacturing capacity within the same timeline as well.

September 30, 2024 / 08:04 IST
Story continues below Advertisement
Syngene has major infrastructure projects slated for completion by FY26.

In a recent management meeting, Syngene said it expects a recovery in H2FY25, Macquarie said in a note. Syngene said it aspires to rebalance its research-to-manufacturing ratio from 60:40 to 50:50, aiming for stronger manufacturing growth.

Syngene International's shares ended almost one percent higher in the previous session at Rs 888. In the past six months, the stocks have gained 25 percent, outperforming the Nifty 50 index which gained 16 percent during the same period. Shares of Syngene International have been giving positive monthly returns since June.

Story continues below Advertisement

Requests for proposals (RPF) have seen a notable uptick year-to-date, indicating solid demand. A request for proposal is a document that is used to gather information from potential vendors or suppliers about products or services. The RFP process can help companies make better decisions by providing a clear outline of what is required and what the vendor needs to deliver.

Follow our live blog for all the market action